These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 26957512)

  • 21. Prevention of prostate cancer: more questions than data.
    Schmid HP; Engeler DS; Pummer K; Schmitz-Dräger BJ
    Recent Results Cancer Res; 2007; 174():101-7. PubMed ID: 17302190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evolving strategies for prostate cancer chemoprevention trials.
    Lieberman R
    World J Urol; 2003 May; 21(1):3-8. PubMed ID: 12682772
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The selenium and vitamin E cancer prevention trial.
    Klein EA; Lippman SM; Thompson IM; Goodman PJ; Albanes D; Taylor PR; Coltman C
    World J Urol; 2003 May; 21(1):21-7. PubMed ID: 12756490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 5-Alpha-reductase inhibitors in diseases of the prostate.
    Carrasquillo RJ; Nealy SW; Wang DS
    Curr Opin Endocrinol Diabetes Obes; 2014 Dec; 21(6):488-92. PubMed ID: 25268733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Can prostate cancer be prevented?
    Klein EA
    Nat Clin Pract Urol; 2005 Jan; 2(1):24-31. PubMed ID: 16474573
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active surveillance of very-low-risk prostate cancer in the setting of active treatment of benign prostatic hyperplasia with 5α-reductase inhibitors.
    Shelton PQ; Ivanowicz AN; Wakeman CM; Rydberg MG; Norton J; Riggs SB; Teigland CM
    Urology; 2013 May; 81(5):979-84. PubMed ID: 23523297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial.
    Fleshner N; Gomella LG; Cookson MS; Finelli A; Evans A; Taneja SS; Lucia MS; Wolford E; Somerville MC; Rittmaster R;
    Contemp Clin Trials; 2007 Nov; 28(6):763-9. PubMed ID: 17573244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Diet and dietary supplement intervention trials for the prevention of prostate cancer recurrence: a review of the randomized controlled trial evidence.
    Van Patten CL; de Boer JG; Tomlinson Guns ES
    J Urol; 2008 Dec; 180(6):2314-21; discussion 2721-2. PubMed ID: 18930254
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prevention of prostate cancer].
    Wirth MP; Hakenberg OW
    Dtsch Med Wochenschr; 2005 Sep; 130(36):2002-4. PubMed ID: 16143928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reduction in the risk of prostate cancer: future directions after the Prostate Cancer Prevention Trial.
    Crawford ED; Andriole GL; Marberger M; Rittmaster RS
    Urology; 2010 Mar; 75(3):502-9. PubMed ID: 20035983
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline.
    Kramer BS; Hagerty KL; Justman S; Somerfield MR; Albertsen PC; Blot WJ; Carter HB; Costantino JP; Epstein JI; Godley PA; Harris RP; Wilt TJ; Wittes J; Zon R; Schellhammer P;
    J Urol; 2009 Apr; 181(4):1642-57. PubMed ID: 19249063
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapeutic prevention studies of prostate cancer.
    Djavan B; Zlotta A; Schulman C; Teillac P; Iversen P; Boccon Gibod L; Bartsch G; Marberger M
    J Urol; 2004 Feb; 171(2 Pt 2):S10-3; discussion S13-4. PubMed ID: 14713746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort.
    Peters U; Littman AJ; Kristal AR; Patterson RE; Potter JD; White E
    Cancer Causes Control; 2008 Feb; 19(1):75-87. PubMed ID: 17943452
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.
    Margel D; Nandy I; Wilson TH; Castro R; Fleshner N
    J Urol; 2013 Dec; 190(6):2039-45. PubMed ID: 23820059
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A nutrient approach to prostate cancer prevention: The Selenium and Vitamin E Cancer Prevention Trial (SELECT).
    Dunn BK; Richmond ES; Minasian LM; Ryan AM; Ford LG
    Nutr Cancer; 2010; 62(7):896-918. PubMed ID: 20924966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of dietary manipulation in biochemical recurrence of prostate cancer after radical prostatectomy.
    Lee CT; Fair WR
    Semin Urol Oncol; 1999 Aug; 17(3):154-63. PubMed ID: 10462319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate cancer prevention: strategies for agent development.
    Parnes HL; House MG; Tangrea JA
    Curr Opin Oncol; 2013 May; 25(3):242-51. PubMed ID: 23518594
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Is There a Future for Chemoprevention of Prostate Cancer?
    Bosland MC
    Cancer Prev Res (Phila); 2016 Aug; 9(8):642-7. PubMed ID: 27099271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Can dutasteride delay or prevent the progression of prostate cancer in patients with biochemical failure after radical therapy? Rationale and design of the Avodart after Radical Therapy for Prostate Cancer Study.
    Schröder FH; Bangma CH; Wolff JM; Alcaraz A; Montorsi F; Mongiat-Artus P; Abrahamsson PA; McNicholas TA; Castro RS; Nandy IM
    BJU Int; 2009 Mar; 103(5):590-6. PubMed ID: 19226424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A review of phase III clinical trials of prostate cancer chemoprevention.
    Thorpe JF; Jain S; Marczylo TH; Gescher AJ; Steward WP; Mellon JK
    Ann R Coll Surg Engl; 2007 Apr; 89(3):207-11. PubMed ID: 17394699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.